Prostaglandins and the management of congenital heart disease.
Either continued patency or closure of the ductus arteriosus is needed to improve survival of infants with certain kinds of congenital heart disease. In many of these infants, the use of prostaglandin (PGE1) or a prostaglandin synthetase inhibitor (indomethacin) permits clinical stabilization in preparation for surgery or makes surgery unnecessary. Although these forms of therapy carry some risk, the risk does not outweigh that of the untreated congenital defects.
D000367:Age Factors; D000527:Alprostadil; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004373:Ductus Arteriosus / Q000187:drug effects*; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D006330:Heart Defects, Congenital / Q000188:drug therapy*; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007231:Infant, Newborn; D011458:Prostaglandins E / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000139:chemically induced
D011458:Prostaglandins E; D000527:Alprostadil; D007213:Indomethacin